Familial myelodysplastic syndromes: a review of the literature
- PMID: 21606161
- PMCID: PMC3186316
- DOI: 10.3324/haematol.2011.043422
Familial myelodysplastic syndromes: a review of the literature
Abstract
Familial cases of myelodysplastic syndromes are rare, but are immensely valuable for the investigation of the molecular pathogenesis of myelodysplasia in general. The best-characterized familial myelodysplastic syndrome is that of familial platelet disorder with propensity to myeloid malignancy, caused by heterozygous germline RUNX1 mutations. Recently, there has been an increase in the number of reported cases, allowing for better understanding of the incidence, clinical features, and pathogenesis of this disorder. These recent cases have highlighted the clinical variability of the disorder and confirmed that many patients lack a bleeding and/or thrombocytopenia history. Additionally, several cases of T-acute lymphoblastic leukemia have now been reported, confirming a risk of lymphoid leukemia in patients with inherited RUNX1 mutations. Furthermore, an increased awareness of clinicians has helped detect a number of additional families affected by inherited myelodysplastic syndromes, resulting in the identification of novel causative mechanisms of disease, such as RUNX1 deficiency resulting from constitutional microdeletions of 21q22 and myelodysplasia-associated with telomerase deficiency. Awareness of predisposition to myelodysplastic syndromes and acute myeloid leukemia in families may be of critical importance in the management of younger patients with myelodysplasia in whom allogeneic hematopoietic stem cell transplantation is considered. Such families should be investigated for inherited deficiencies of RUNX1 and/or telomerase to prevent the use of an affected sibling as a donor for transplantation. Here we provide an update on familial platelet disorder in addition to a review of other known familial myelodysplastic syndromes.
Comment in
-
Managing individuals with propensity to myeloid malignancies due to germline RUNX1 deficiency.Haematologica. 2011 Dec;96(12):1892-4. doi: 10.3324/haematol.2011.053710. Epub 2011 Aug 31. Haematologica. 2011. PMID: 21880633 Free PMC article. No abstract available.
Similar articles
-
A de novo germline RUNX1 variant preceding development of concurrent T-lymphoblastic leukemia and myelodysplastic syndrome.Leuk Lymphoma. 2024 Sep;65(9):1357-1361. doi: 10.1080/10428194.2024.2347577. Epub 2024 May 11. Leuk Lymphoma. 2024. PMID: 38733629
-
RUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM).Semin Hematol. 2017 Apr;54(2):75-80. doi: 10.1053/j.seminhematol.2017.04.006. Epub 2017 Apr 13. Semin Hematol. 2017. PMID: 28637620 Review.
-
Familial myelodysplasia and acute myeloid leukaemia--a review.Br J Haematol. 2008 Jan;140(2):123-32. doi: 10.1111/j.1365-2141.2007.06909.x. Br J Haematol. 2008. PMID: 18173751 Review.
-
[Clinical and genetic background of familial myelodysplasia and acute myeloid leukemia].Orv Hetil. 2016 Feb 21;157(8):283-9. doi: 10.1556/650.2016.30375. Orv Hetil. 2016. PMID: 26876264 Review. Hungarian.
-
Familial platelet disorder with propensity to acute myelogenous leukemia: genetic heterogeneity and progression to leukemia via acquisition of clonal chromosome anomalies.Genes Chromosomes Cancer. 2004 Jul;40(3):165-71. doi: 10.1002/gcc.20030. Genes Chromosomes Cancer. 2004. PMID: 15138996
Cited by
-
How I diagnose and manage individuals at risk for inherited myeloid malignancies.Blood. 2016 Oct 6;128(14):1800-1813. doi: 10.1182/blood-2016-05-670240. Epub 2016 Jul 28. Blood. 2016. PMID: 27471235 Free PMC article.
-
Epigenetic Research in Stem Cell Bioengineering-Anti-Cancer Therapy, Regenerative and Reconstructive Medicine in Human Clinical Trials.Cancers (Basel). 2020 Apr 21;12(4):1016. doi: 10.3390/cancers12041016. Cancers (Basel). 2020. PMID: 32326172 Free PMC article. Review.
-
Linkage between the mechanisms of thrombocytopenia and thrombopoiesis.Blood. 2016 Mar 10;127(10):1234-41. doi: 10.1182/blood-2015-07-607903. Epub 2016 Jan 19. Blood. 2016. PMID: 26787737 Free PMC article. Review.
-
Diagnostics and Prognostication of Myelodysplastic Syndromes.Ann Lab Med. 2017 Nov;37(6):465-474. doi: 10.3343/alm.2017.37.6.465. Ann Lab Med. 2017. PMID: 28840983 Free PMC article. Review.
-
Inherited platelet dysfunction and hematopoietic transcription factor mutations.Platelets. 2017 Jan;28(1):20-26. doi: 10.1080/09537104.2016.1203400. Epub 2016 Jul 27. Platelets. 2017. PMID: 27463948 Free PMC article. Review.
References
-
- Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536–42. - PubMed
-
- Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood. 2008;112(1):45–52. - PubMed
-
- Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361(19):1872–85. - PubMed
-
- Larson RA, Wang Y, Banerjee M, Wiemels J, Hartford C, Beau MML, et al. Prevalence of the Inactivating 609C→T Polymorphism in the NAD(P)H:Quinone Oxidoreductase (NQO1) Gene in Patients With Primary and Therapy-Related Myeloid Leukemia. Blood. 1999;94(2):803–7. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical